Oxford Science Park, Oxford, UK, 5 March, 2008
PharmaVentures announced today the appointment of Anne Vindenes Allen MSc as Chief Operating Officer of PharmaDeals, the new publishing division of PharmaVentures Ltd. Fintan Walton, PhD, PharmaVentures’ Chief Executive Officer says, “We have a large and loyal following for the PharmaDeals database within the pharmaceutical and biotechnology business sector, and have plans to roll out some truly exciting developments in the coming months. We are delighted Anne will join us to steer these developments. Her experience of managing complex web technology implementations combined with her publishing expertise will be invaluable in helping us position our products to better serve our discerning customers.”
Anne says, “The PharmaDeals database is internationally renowned for the quality of its content, and not least its depth of coverage. We are extremely fortunate in having world leading experts at hand here at PharmaVentures to advise us in taking this premier resource to the next level”. In addition to directing PharmaDeals, Anne will take forward PharmaDeals Reports publications, a portfolio of books and reports focused on deals and alliances. Ms Allen will also contribute to the technical development of PharmaTelevision, the innovating web television channel.
A life scientist by training, Anne gained her publishing and management experience over nine years at Elsevier Science, the world’s largest STM publisher, latterly as Publisher for a highly successful environmental sciences programme. Her knowledge and interest in new publishing technologies came in good stead as Editorial Director at Infotrieve Inc, where she contributed to the conceptual development of the Life Science Resource Centre database product. As Managing Director of TheScientificWorld Ltd, the scholarly publisher for biomedical sciences, Anne was responsible for designing and implementing their innovating scholarly journal platform. “It’s an exciting new challenge; this is a smart company with smart ideas serving a high level audience. We have to deliver real quality of product and service – and my aim would be to ensure that PharmaDeals continues to be the preferred choice for all pharmaceutical and biotechnology companies, and also interested stakeholders in academia worldwide.”
- ends -